<DOC>
	<DOCNO>NCT00218855</DOCNO>
	<brief_summary>The purpose study test effect thalidomide patient multiple myeloma . The patient receive either thalidomide placebo tablet ( neither patient doctor know give ) addition ordinary chemotherapeutic drug multiple myeloma . We find long time patient stay free disease long time live , evaluate whether thalidomide beneficial drug disease .</brief_summary>
	<brief_title>Thalidomide Patients With Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description>Thalidomide recently emerge effective treatment patient myeloma refractory conventional chemotherapy . So far limited experience available thalidomide newly diagnose myeloma . Therefore Nordic Myeloma Study Group decide perform trial compare traditional melphalan-prednisone therapy melphalan-prednisone + thalidomide/placebo . The study design multicentre double-blind randomise placebo-controlled trial . Mainly patient &gt; 65 year age include since patient &lt; 65 year treat high dose chemotherapy autologous stem cell support . The primary end-point overall survival . Secondary end-points quality life , response rate , time response , response duration toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients multiple myeloma need treatment Previous treatment multiple myeloma Need high dose chemotherapy autologous stem cell support Women fertile age Psychiatric disease mental reduction lead lack cooperation Lack consent Life expectancy 3 month Active cancer etiology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Phase 3 , randomise , double blind study</keyword>
	<keyword>thalidomide</keyword>
</DOC>